The dementia vaccine will be tested in the next 3 years

Alzheimer's and other dementia are becoming popular in the elderly, causing consequences for themselves and their families. Therefore, the prevention and treatment of this disease is an important task of medicine.

Recently, scientists in the United Kingdom and the United States have made significant progress in finding a vaccine that can stop it and even in some cases, reverse the onset of dementia, Alzheimer's disease and Other related diseases.

This is considered a major problem in the treatment of these diseases and can be considered as a new drug targeting the tau proteins found in nerve fiber plexus and abnormal beta-amyloid , which can accumulate and cause Alzheimer's disease.

According to researcher Nikolai Petrovsky from Flinders University, Australia, in the event that things go well as expected, vaccines can be tested on humans for at least 2 to 3 years."If we succeed in pre-clinical trials, we may come close to one of the most important milestones in the history of world medicine," he said.

In the next 3 to 5 years we may approach one of the most important milestones in the history of world medicine.

Petrovsky told 891 ABC that antibodies in this vaccine act like trucks pulling, coming and taking away proteins that are damaged by disease. Two separate vaccines, one specialized in beta-amyloid and the other for tau proteins , have been combined to create new treatments.

The specialized vaccine that attacks tau proteins is the latest and most effective finding in reversing the damage caused in the brain. The anti-beta-amyloid type works best if it is considered a precautionary measure for people at risk of dementia. The combination of these two types will bring better results, based on recent tests carried out on mouse groups.

In other words, part of the new vaccine will focus on the triggers of Alzheimer's disease and others will focus on the factors that make the disease worse.

Petrovsky explains: "This vaccine can be used to provide people at specific ages, preferably 50 years old with the goal of preventing dementia. It also has the ability to help. People in the early stages of dementia try to reverse this process. "

Every year, 7.5 million Alzheimer's cases are diagnosed worldwide. Now with an aging population and an increase in type 2 diabetes (a major factor in Alzheimer's disease) in Western society, this outlook is extremely bleak. Alzheimer's is the most common cause of dementia in old age.

In recent years, hundreds of compounds have been tested to find a way to prevent dementia, but only 0.5 percent of them are effective in reducing the effects of this disease.

Alzheimer's and dementia are becoming common in people over 50 years old.(Photo: Mister GC / Flickr).

It is not a great success rate and for this treatment to become a reality, a state-of-the- art MultiTEP vaccine platform has been combined to target proteins that cause problems. The brain is the most effective way.

Scientists from Flinders University have worked closely with the Institute of Molecular Medicine (IMM) and the University of California, Irvine (UCI), USA to create a new formula.

According to Michael Agadjanyan of the Institute of Molecular Medicine, researchers not only make MultiTEP antibodies cling to their targets, they also avoid creating harmful reactions from the body's immune system.

While we do not know whether this vaccine will be effective on humans and it will take several years to test, scientists still have great hope about the potential of a new vaccine that can stop it. Preventing health problems is happening quite seriously nowadays.

The latest research results have been published in Scientific Reports.